Portage Point Partners, a business advisory and interim management firm, promoted Mark Berger to managing director, Zach Rose to senior vice president and Ryan Mersch to vice president.

Berger joined Portage Point in January 2019, bringing almost 15 years of experience advising stakeholders during periods of underperformance and transition. Since joining Portage Point in 2019, he served as chief restructuring officer for Energold Drilling during its CCAA proceedings, as plan administrator for Synergy Pharmaceuticals and as financial advisor to Dura Automotive during its ongoing Chapter 11 proceedings.

Rose joined Portage Point as its second full-time employee in 2016 and has substantial experience spanning investment banking and advisory services. Since joining Portage Point, Rose has played a pivotal role managing the firm’s growing team of professionals while leading execution efforts across more than 25 engagements comprising a broad-range of complex situations. Several of these engagements have earned industry-wide recognition including Large Turnaround of the Year (2019) and Corporate Transaction of the Year (2017).

During 2019, Rose led the day-to-day implementation of large-scale transformation and performance improvement initiatives for a $200 million subsidiary of a publicly-traded company. Additionally, he provided meaningful contributions to the restructuring efforts at Energold and Dura. Currently,

Mersch joined Portage Point as its third full time employee and has significant experience working as an investment banker and advisor. He has served in various capacities supporting clients during performance improvement, interim management and financial restructuring engagements. In 2019, he supported financial advisor engagements for the Total Finance Investment Chapter 11 and Dura as well as interim management and performance improvement engagements for the Loot Crate Chapter 11 proceeding (chief restructuring officer) and performance improvement project related to a $600 million powersports distribution and manufacturing business (interim chief operating officer).

Currently, Mersch serves as the daily execution leader for publicly-traded Melinta Pharmaceuticals during its ongoing Chapter 11 proceedings.